Open AccessLong-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis
Author(s) -
Dario Roccatello,
Simone Baldovino,
Daniela Rossi,
Majid Mansouri,
Carla Naretto,
M. Gennaro,
Rossana Cavallo,
Mirella Alpa,
Piera Costanzo,
Osvaldo Giachino,
Gianna Mazzucco,
L. M. Sena
Publication year - 2004
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfh469
Subject(s) - medicine , rituximab , gastroenterology , immunology , cd20 , proteinuria , lymphoma , erythrocyte sedimentation rate , vasculitis , bone marrow , kidney , disease
Type II mixed cryoglobulinaemia (MC) is a systemic vasculitis, associated in most cases with hepatitis C virus (HCV) infection, and sustained by proliferation of oligoclonal cells. Systemic B-cell depletion and clinical remission can be achieved in non-Hodgkin lymphoma by a human/mouse chimeric monoclonal antibody that specifically reacts with the CD20 antigen (Rituximab). Similar effects could be expected in type II MC.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom